| Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib NA O'Brien, BC Browne, L Chow, Y Wang, C Ginther, J Arboleda, ... Molecular cancer therapeutics 9 (6), 1489-1502, 2010 | 365 | 2010 |
| Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer B Ryan, N O'donovan, B Browne, C O'shea, J Crown, ADK Hill, ... British journal of cancer 92 (1), 120-124, 2005 | 216* | 2005 |
| Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells F Hochgräfe, L Zhang, SA O'Toole, BC Browne, M Pinese, A Porta Cubas, ... Cancer research 70 (22), 9391-9401, 2010 | 211 | 2010 |
| HER-2 signaling and inhibition in breast cancer BC Browne, N O'Brien, MJ Duffy, J Crown, N O'Donovan Current Cancer Drug Targets 9 (3), 419-438, 2009 | 149 | 2009 |
| Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells BC Browne, J Crown, N Venkatesan, MJ Duffy, M Clynes, D Slamon, ... Annals of Oncology 22 (1), 68-73, 2011 | 130 | 2011 |
| Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway DR Croucher, F Hochgräfe, L Zhang, L Liu, RJ Lyons, D Rickwood, ... Cancer research 73 (6), 1969-1980, 2013 | 96 | 2013 |
| Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors S Rani, C Corcoran, L Shiels, S Germano, S Breslin, S Madden, ... Cancer research 74 (14), 3821-3833, 2014 | 53 | 2014 |
| PP2A inhibition overcomes acquired resistance to HER2 targeted therapy MSJ McDermott, BC Browne, NT Conlon, NA O’Brien, DJ Slamon, ... Molecular cancer 13, 1-12, 2014 | 50 | 2014 |
| Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours BC Browne, AJ Eustace, S Kennedy, NA O’Brien, K Pedersen, ... Breast cancer research and treatment 136, 717-727, 2012 | 49 | 2012 |
| Global characterization of signalling networks associated with tamoxifen resistance in breast cancer BC Browne, F Hochgräfe, J Wu, EKA Millar, J Barraclough, A Stone, ... The FEBS journal 280 (21), 5237-5257, 2013 | 48 | 2013 |
| Functional characterization of cancer-associated Gab1 mutations C Ortiz-Padilla, D Gallego-Ortega, BC Browne, F Hochgräfe, CE Caldon, ... Oncogene 32 (21), 2696-2702, 2013 | 39 | 2013 |
| Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation MTH Abreu, WE Hughes, K Mele, RJ Lyons, D Rickwood, BC Browne, ... Molecular biology of the cell 22 (1), 105-116, 2011 | 36 | 2011 |
| Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL AJ Eustace, NT Conlon, MSJ McDermott, BC Browne, P O’Leary, ... Bmc Cancer 18, 1-14, 2018 | 33 | 2018 |
| HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer A Canonici, L Ivers, NT Conlon, K Pedersen, N Gaynor, BC Browne, ... Investigational new drugs 37, 441-451, 2019 | 28 | 2019 |
| HER2-targeted tyrosine kinase inhibitors cause therapy-induced-senescence in breast cancer cells MSJ McDermott, N Conlon, BC Browne, A Szabo, NC Synnott, NA O’Brien, ... Cancers 11 (2), 197, 2019 | 28 | 2019 |
| Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells MSJ McDermott, A Canonici, L Ivers, BC Browne, SF Madden, NA O'brien, ... International Journal of Oncology 50 (6), 2221-2228, 2017 | 27 | 2017 |
| Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines. A Canonici, K Pedersen, B Browne, M McDermott, N Walsh, J Crown, ... Journal of Clinical Oncology 31 (15_suppl), 632-632, 2013 | 9 | 2013 |
| Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells. M McDermott, B Browne, J Crown, N O'Brien, DJ Slamon, N O'Donovan Journal of clinical oncology 29 (15_suppl), 583-583, 2011 | 5 | 2011 |
| The role of receptor tyrosine kinase signalling in HER-2-positive cells and Trastuzumab (Herceptin) Resistance in Breast Cancer B Browne Dublin City University, 2009 | 5 | 2009 |
| Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells. M McDermott, B Browne, A Szabo, J Crown, N O'Donovan Journal of Clinical Oncology 34 (15_suppl), e12092-e12092, 2016 | 4 | 2016 |
